You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, September 2016
|
| DOI | 10.1186/s40425-016-0155-8 |
| Pubmed ID | |
| Authors |
Elizabeth I. Buchbinder, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Sandra Aung, Howard L. Kaufman, Marc S. Ernstoff, Girald P. Miletello, Brendan D. Curti, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Sigrun Hallmeyer, Joseph I. Clark, Rene Gonzalez, John M. Richart, Joe Lutzky, Michael A. Morse, Ryan J. Sullivan, David F. McDermott |
| Abstract |
High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients. However, not all patients respond to immune checkpoint blockade and subsequent therapeutic options need to be explored. The PROCLAIM database was queried for patients with metastatic melanoma who had received HD IL-2 after treatment with ipilimumab or without prior ICB. Patient characteristics, toxicity and efficacy were analyzed. A total of 52 metastatic melanoma patients were treated with high dose IL-2 after ipilimumab and 276 patients were treated with high dose IL-2 without prior ICB. The overall response rate in the prior ipilimumab group was 21 % as compared to 12 % in the group that had not received prior ipilimumab. The median overall survival, measured from the initiation of HD IL-2 therapy, was 19.3 months in the prior ipilimumab group and 19.4 months in the no prior ICB group. Toxicities observed on HD IL-2 were relatively equivalent between the groups although there were cases of CTLA4 antibody-induced colitis reported after HD IL-2 treatment and a CTLA4 antibody-induced colitis related death. In this retrospective analysis HD IL-2 therapy displayed antitumor activity in melanoma patients who progressed following treatment with ipilimumab. Most HD IL-2 toxicity was not worsened by prior ipilimumab therapy except for one treatment related death from colitis. Care should be taken to avoid reactivation of CTLA4 antibody-induced colitis. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 26% |
| Student > Bachelor | 4 | 12% |
| Student > Doctoral Student | 3 | 9% |
| Student > Ph. D. Student | 3 | 9% |
| Student > Master | 3 | 9% |
| Other | 6 | 18% |
| Unknown | 6 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Agricultural and Biological Sciences | 3 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Immunology and Microbiology | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 7 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2018.
All research outputs
#1,981,423
of 25,374,917 outputs
Outputs from Journal for Immunotherapy of Cancer
#526
of 3,421 outputs
Outputs of similar age
#33,644
of 327,911 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#7
of 19 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,911 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.